Diabetes

  • A group of people cheering inside the Nasdaq building, standing behind a podium.
    Image attribution tooltip
    Permission granted by Beta Bionics
    Image attribution tooltip
    Q&A

    Beta Bionics CEO, CFO on how to take a company public

    CEO Sean Saint and CFO Stephen Feider spoke about what’s different now that the company is public and the long journey of pursuing an IPO.

    By • June 2, 2025
  • A person looks at a smartwatch while walking past packaged produce.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Why Medtronic plans to spin out its diabetes business

    While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on segments with higher margins.

    By • May 22, 2025
  • The exterior of Medtronic's Minnesota operational headquarters is shown along with its reflection in a pool of water.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic plans to spin off diabetes business within 18 months

    CEO Geoff Martha told investors the split simplifies Medtronic’s portfolio, while creating a stand-alone diabetes tech competitor.

    By • May 21, 2025
  • Professional photo of Kevin Sayer
    Image attribution tooltip
    Permission granted by Dexcom
    Image attribution tooltip

    Dexcom CEO says CGMs fit MAHA agenda ‘very nicely’; Tandem preps for new products

    In earnings calls, diabetes tech companies had less to say about tariffs and focused more on future growth.

    By • May 16, 2025
  • Professional photo of Dev Kurdikar
    Image attribution tooltip
    Permission granted by Embecta
    Image attribution tooltip

    Embecta restructures again, outlines tariff costs

    The diabetes tech company announced a second restructuring after ending its insulin patch-pump program.

    By • May 13, 2025
  • An exterior photo of a corporate campus shows flat buildings and a grassy lawn.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche plans $550M expansion of Indianapolis site to manufacture CGMs

    Roche Diagnostics plans to produce glucose monitors at the site within three years and prepare for future generations of its sensors.

    By • May 12, 2025
  • Professional photo of Ashley McEvoy
    Image attribution tooltip
    Permission granted by Insulet
    Image attribution tooltip

    New Insulet CEO Ashley McEvoy sets priorities

    The diabetes tech company raised its expectations for revenue and gross margins, despite the impact of tariffs.

    By • May 9, 2025
  • Professional photo of Osagie Ebekozien
    Image attribution tooltip
    Permission granted by The American Diabetes Association
    Image attribution tooltip
    Q&A

    ADA’s Osagie Ebekozien on diabetes tech for Type 2, new CGM standards

    Ebekozien, chief quality officer of the American Diabetes Association, said the nonprofit is seeing a shift with more devices authorized for Type 2 diabetes.

    By • May 9, 2025
  • Epic's logo on top of its booth at HIMSS23.
    Image attribution tooltip
    Rebecca Pifer/MedTech Dive
    Image attribution tooltip

    Abbott integrates diabetes data into Epic’s electronic health records

    Linking the systems will allow clinicians to view glucose data captured by Libre glucose sensors within Epic’s systems.

    By • May 1, 2025
  • A black reader is shown on top of a phone with a blood glucose reading.
    Image attribution tooltip
    Permission granted by Senseonics
    Image attribution tooltip

    Senseonics, Sequel partner to use 1-year CGM in automated insulin dosing system

    The partnership extends the compatibility of Sequel’s Twiist system to allow people with Type 1 diabetes to pair the device with Senseonics’ Eversense 365 CGM.

    By • April 30, 2025
  • Professional photo of Ashley McEvoy
    Image attribution tooltip
    Permission granted by Insulet
    Image attribution tooltip

    Ashley McEvoy named Insulet CEO

    McEvoy, the former leader of Johnson & Johnson’s medtech business, started immediately. Jim Hollingshead, who was CEO of Insulet for three years, resigned on Monday but will work as a consultant.

    By • April 28, 2025
  • A person stands outside wearing a small, square device with a cord on their belt.
    Image attribution tooltip
    Permission granted by Medtronic
    Image attribution tooltip

    Medtronic seeks FDA nod for insulin pump, furthering Abbott collab

    Receiving FDA clearance would allow Medtronic to pair its pumps with a glucose monitor being developed for the company by Abbott.

    By • April 24, 2025
  • A person holds a phone, wearing a white patch on their forearm and an insulin pump on their hip.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic gets FDA approval to use Simplera Sync glucose sensor with insulin pumps

    The updated device allows users to pair the sensor with Medtronic’s insulin pumps, and is expected to grow the company’s diabetes business.

    By • April 21, 2025
  • The entrance to Illumina's San Diego campus.
    Image attribution tooltip
    Courtesy of Illumina
    Image attribution tooltip

    Illumina, Tempus AI partner to drive genomic testing beyond cancer

    The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing across all major diseases.

    By • April 18, 2025
  • A person smiles and holds a spoon. A white patch is on their right upper arm.
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip

    Dexcom nets FDA clearance for 15-day CGM

    The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun Singh said.

    By • April 10, 2025
  • A person wearing gloves hangs a clear bag with fluid on a metal hook.
    Image attribution tooltip
    Bevan Goldswain via Getty Images
    Image attribution tooltip
    Trump tariffs

    Tariffs send healthcare industry into ‘unchartered waters’

    Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain. Wall Street, meanwhile, said medtech businesses will face pressure, particularly diabetes tech firms.

    By Susanna Vogel , • April 4, 2025
  • Professional photo of Jordan Pinsker
    Image attribution tooltip
    Permission granted by Tandem Diabetes Care
    Image attribution tooltip

    Tandem eyes Medicare coverage expansion for Type 2

    CMO Jordan Pinsker said Tandem hopes to expand Medicare coverage of its automated insulin delivery systems using new data shared at ATTD.

    By • March 31, 2025
  • A black, square device with tubing connected to a patch is next to a phone that says "Beta Bionics" and another patch that says DexcomG6
    Image attribution tooltip
    Courtesy of Beta Bionics
    Image attribution tooltip

    Newly public Beta Bionics reports sales surge; Dexcom hires CCO

    Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former Masimo exec Jon Coleman joined Dexcom, and Sibionics’ CGM earned the CE mark.

    By • March 28, 2025
  • The Dexcom G7 Continuous Glucose Monitoring (CGM) System
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip

    Dexcom rejects claims of unauthorized device changes in FDA warning letter

    A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its glucose sensors.

    By • March 27, 2025
  • The Dexcom G7 Continuous Glucose Monitor
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip

    Dexcom’s FDA warning letter reveals unauthorized changes to sensors

    Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, according to the warning letter.

    By • March 26, 2025
  • Professional photo of Jake Leach
    Image attribution tooltip
    Permission granted by Dexcom
    Image attribution tooltip
    Q&A

    Dexcom COO on 15-day glucose sensor, Type 2 coverage

    Jake Leach caught up with MedTech Dive during the ATTD conference to discuss new data on the company’s glucose monitors and an FDA warning letter.

    By • March 25, 2025
  • Nick Jonas poses in front of a glowing background, wearing a small, round device on his upper arm
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip
    News roundup

    Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data

    Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

    By • March 20, 2025
  • Professional photo of Mark Field
    Image attribution tooltip
    Retrieved from Insulet on March 18, 2025
    Image attribution tooltip

    Insulet Chief Technology Officer Mark Field leaves

    Amit Guliani, group vice president of software engineering, was named acting chief technology officer, effective immediately.

    By • March 18, 2025
  • Dexcom's Stelo continuous glucose monitor.
    Image attribution tooltip
    Courtesy of Business Wire
    Image attribution tooltip

    Dexcom receives warning letter based on FDA inspections of 2 plants

    The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek clearance for new products.

    By • March 10, 2025
  • The entrance to Illumina's San Diego campus.
    Image attribution tooltip
    Courtesy of Illumina
    Image attribution tooltip

    Illumina to lay off 96 San Diego employees

    The latest job cuts at Illumina’s California headquarters are not part of a broad-based reduction, a company spokesperson said.

    By • Feb. 28, 2025